| abstract |
The present application discloses a pharmaceutical combination for preventing cancer, delaying the progression of cancer, or treating cancer, wherein the pharmaceutical combination exhibits a synergistic effect. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody and a RAF inhibitor against PD-1. This application also discloses a method for preventing cancer, delaying cancer progression, or treating cancer in a subject, comprising administering to said subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 And a therapeutically effective amount of an RAF inhibitor. |